Patient Advocacy Groups and Clinical Trials: Impressions from DIA 2018


The Health Decisions team at DIA 2018 left with the impression that the biopharma industry values relationships with patient advocacy groups but use of such groups in study planning and protocol development remains the exception rather than the rule. Health Decisions' Chief Medical Officer Andrea Lukes, MD, MHSc, FACOG, chaired a DIA forum entitled "From [...]